Akebia Therapeutics, Inc.AKBANASDAQ
Loading
Operating Income Growth AcceleratingAccelerating
Percentile Rank100
3Y CAGR+28.3%
Studio
Year-over-Year Change

Year-over-year operating income growth rate

3Y CAGR
+28.3%/yr
Annual compound
Percentile
P100
Near historical high
vs 3Y Ago
2.1x
Strong expansion
Streak
1 yr
Consecutive growthAccelerating
PeriodValue
2025146.56%
2024-9.11%
202342.74%
202269.46%
202129.99%
2020-31.97%
2019-60.71%
2018-122.91%
201741.44%
2016-121.84%